Resources
45 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/17/2024
This article discusses strategies to recruit primary care providers who will implement a medication for opioid use disorder integrated care model. The Pennsylvania Project, Project RAMP, was guided by a framework highlighting design, recruitment, pre-implementation, and implementation processes. The study covers the implementation sites that were recruited, the planning and implementation activities, and evaluation of the processes.
Posted 4/19/2024
Researchers assessed whether there was a connection between buprenorphine dose and time to treatment discontinuation when fentanyl is prevalent. The results showed that a 24mg dose of buprenorphine remained in treatment longer than those prescribed 16mg. Therefore, higher buprenorphine doses could be considered to help improve treatment retention.
Posted 4/19/2024
Researchers assessed disparities in the availability of hospital-based transitional opioid programs for substance use disorder (SUD) in urban and rural settings.
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 4/12/2024
Researchers used data from electronic license renewals in 2021 to examine what factors affect the likelihood of providing medication-assisted treatment (MAT) for opioid use disorder. Physicians and nurse practitioners who were younger, practiced in a public or community health center, and offered a sliding fee scale in their practice had a greater likelihood of providing MAT.
Posted 4/5/2024
This study assessed the associations between insurance status and 6-month retention of patients with opioid use disorder on telehealth platforms. Patients whose insurance paid for their care were most likely to still be receiving buprenorphine 6 months after starting treatment. Uninsured patients who paid cash were more likely to be in treatment at 6 months than people with insurance that did not cover their care. Findings showed an association between in-network insurance benefits and retention, which may affect the opioid crisis.
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.
Posted 10/23/2023 (updated 3/27/2024)
Posted 6/8/2023 (updated 3/27/2024)
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD) with a relatively low rate of triggering precipitated withdrawal in patients. Increased precipitated withdrawal rates have become a concern for practitioners in emergency departments when treating with buprenorphine with the prevalence of fentanyl in the drug supply.
Posted 4/28/2023 (updated 3/27/2024)
The study tested a care coordination model in six rural primary care sites during the peak of the COVID-19 pandemic, July 2020 to January 2021. Each clinic tracked patients with opioid use disorder (OUD) as they received medication treatment delivered by an external telemedicine provider.